IPM Take
This is early-stage precision oncology becoming operational. The story is not only Tecentriq. It is whether every patient with resected stage III colon cancer has mismatch-repair status known before the adjuvant window starts closing. If FDA approves this indication, dMMR/MSI-H testing stops being a pathology detail. It becomes the door to recurrence-prevention treatment.
Executive Summary
Roche announced that FDA accepted its supplemental Biologics License Application for Tecentriq, atezolizumab, and Tecentriq Hybreza in combination with chemotherapy as adjuvant treatment for stage III dMMR/MSI-H colon cancer after surgery. FDA granted Priority Review and is expected to make a decision by 9 October 2026. The application is based on the phase III ATOMIC trial, published in The New England Journal of Medicine, where adding atezolizumab to mFOLFOX6 reduced the risk of recurrence or death by 50% compared with chemotherapy alone in resected stage III dMMR colon cancer.
Why it matters
- Pathology: dMMR/MSI-H status must be identified reliably and early after surgery.
- Clinicians: Adjuvant colon cancer decisions are moving beyond stage and standard risk factors.
- Regulators: Priority Review signals a potentially important option in a defined early-stage population.
- Payers: Reimbursement will need to include both the medicine and the testing pathway that identifies eligibility.
Colon cancer precision medicine has often lived in the metastatic conversation. This FDA Priority Review shifts the pressure earlier.
Stage III colon cancer is treated with curative intent, but recurrence remains a real threat. Roche notes that nearly one in three patients with stage III colon cancer relapse within five years. For patients with dMMR/MSI-H disease, immunotherapy may be especially relevant, but that biology only matters if the system finds it in time.
The ATOMIC data make the access question difficult to avoid. In resected stage III dMMR colon cancer, adding atezolizumab to mFOLFOX6 significantly improved disease-free survival compared with mFOLFOX6 alone. Roche reports a 50% reduction in recurrence or death risk, with 36-month disease-free survival of 86% for atezolizumab plus FOLFOX6 versus 76% for chemotherapy alone.
This is where the pathway becomes political. If FDA approves the indication, the gap will not only be whether hospitals can buy Tecentriq. It will be whether patients are tested, whether results return fast enough, whether oncologists act on them, and whether payers recognise the full diagnostic-treatment pathway.
For IPM, this is a clean last-mile story. The drug may be the headline, but eligibility is the real access gate.
